The Translational Breast Cancer Research Consortium was well represented at the 2020 ASCO Annual Meeting. Presentations included:

A Multiparameter Classifier to Predict Response to Lapatinib plus Trastuzumab (LT) without Chemotherapy in HER2-positive Breast Cancer (TBCRC 023); Abstract # 1011

A Phase II Trial of Azetolizumab (anti-PDL1) with Carboplatin in Patients with Metastatic Triple Negative Breast Cancer (TBCRC 043 ); Abstract #TPS1112

Immunotherapy and Chemotherapy Combination for Chest Wall Disease: TBCRC 044 trial; Abstract #TPS1114

TBCRC 048: A phase II Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Damage Response (DDR) Pathway Genes (Olaparib Expanded); Abstract #1002